Back to results
US 2026/0048115 A1Published application
Preparation of influenza virus vaccine antigens
AssigneeSeqirus UK Limited
InventorsChristoph HAUSSMANN, Frank HAUSCHILD, Bjorn JOBST
Life of this patent
Estimating the term…
Abstract
A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
Claims16
1-12. (canceled)
13:
- A process for preparing an influenza vaccine, comprising:
- preparing a hemagglutinin-containing antigen preparation obtained from an influenza virus by disrupting influenza virions, wherein the disrupting of influenza virions comprises:
- (i) obtaining a composition comprising influenza virions in the absence of detergent;
- (ii) performing ultrafiltration or diafiltration on the virion-containing composition;
- (iii) adding a first detergent to the filtered virion-containing composition without splitting the virions, wherein the amount of the first detergent is less than 1.5 g/L;
- (iv) inactivating the influenza virions;
- and
- (v) splitting the inactivated virions with a second detergent;
- wherein further quantities of the first detergent are added after step (v);
- and
- preparing the influenza vaccine from the hemagglutinin-containing antigen preparation.
8 more elements
14:
- The process of claim 13, wherein the first and second detergents are different.
15:
- The process of claim 13, wherein addition of the first detergent after step (v) occurs prior to a further ultrafiltration/diafiltration step.
16:
- The process of claim 13, wherein the second detergent is an ionic detergent.
17:
- The process of claim 13, wherein the second detergent is Cetyltrimethylammonium bromide.
18:
- The process of claim 13, wherein the first detergent is polysorbate 80.
19:
- The process of claim 13, wherein the influenza virions are from an influenza A virus.
20:
- The process of claim 13, wherein the influenza virions are from an influenza A virus of H5 hemagglutinin subtype.
21:
- The process of claim 13, wherein the influenza virions are prepared from mammalian cell culture.
22:
- The process of claim 13, wherein the influenza virions are prepared from eggs.
23:
- The process of claim 13, wherein the influenza vaccine comprises antigen from more than one strain of influenza virus.
24:
- The process of claim 13, wherein the influenza vaccine comprises hemagglutinin at 7.5 μg per influenza virus strain.
25:
- The process of claim 13, wherein the influenza vaccine comprises hemagglutinin at 15 μg per influenza virus strain.
26:
- The process of claim 13, wherein the influenza vaccine comprises an adjuvant.
27:
- The process of claim 26, wherein the adjuvant comprises an oil-in-water emulsion.